CARLSMED, INC. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Carlsmed reported Q2 2026 revenue of $18.9M (57% YoY growth) and raised full-year 2026 guidance to $74–78M (from prior $72–77M), representing >50% growth versus 2025. Gross margin expanded 340 bps to 76.8%. However, net loss widened to $10.5M (Q2) vs. $6.8M prior-year; operating expenses jumped 66% YoY to $25.6M; adjusted EBITDA loss deepened to $8.6M. Cash position was $89.3M as of June 30, 2026. CMS finalized favorable reimbursement for lumbar aprevo procedures effective October 1, 2026.
Why this rating
Strong revenue growth (57% YoY) and guidance raise relative to ~$50M company scale; CMS reimbursement approval is material catalyst. However, losses and OpEx expansion offset optimism—profitability timeline unclear despite margin expansion.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.